Kim Hyeong Su, Kim Jung Han, Jang Hyun Joo
Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea.
Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung, Republic of Korea.
J Cancer. 2019 Jun 2;10(11):2560-2567. doi: 10.7150/jca.29184. eCollection 2019.
Fibroblast growth factor receptor-2 () gene is amplified in up to 15% of patients with gastric cancer (GC). However, the prognostic significance of amplification has been controversial. This meta-analysis was conducted to evaluate the clinicopathological impacts of amplification in patients with GC. We performed a systematic computerized search of the electronic databases of PubMed, PMC, EMBASE, Web of Science, and Google Scholar and selected studies assessing the correlation of amplification with pathologic features and/or prognosis in gastric adenocarcinoma. From eight studies, 2,377 patients were included in the pooled analysis of odds ratios (ORs) with 95% confidence intervals (CIs) for pathologic findings and hazard ratios (HRs) with 95% CIs for overall survival. amplification was significantly associated with LN metastasis (OR = 3.93, 95% CI: 2.22-6.96, p < 0.00001) and poorly differentiated adenocarcinoma (OR = 2.36, 95% CI: 1.03-5.39, p = 0.04). In addition, patients with GC harboring amplification showed significantly worse survival (HR = 2.09, 95% CI: 1.68-2.59, p < 0.00001), compared with patients with -unamplified GC. In conclusion, this meta-analysis indicates that amplification is an adverse prognostic factor in patients with GC.
成纤维细胞生长因子受体2（）基因在高达15%的胃癌（GC）患者中发生扩增。然而，扩增的预后意义一直存在争议。本荟萃分析旨在评估扩增对GC患者临床病理的影响。我们对PubMed、PMC、EMBASE、Web of Science和谷歌学术等电子数据库进行了系统的计算机检索，并选择了评估扩增与胃腺癌病理特征和/或预后相关性的研究。在八项研究中，2377例患者被纳入合并分析，计算病理结果的比值比（OR）及其95%置信区间（CI），以及总生存的风险比（HR）及其95%CI。扩增与淋巴结转移显著相关（OR = 3.93，95%CI：2.22 - 6.96，p < 0.00001）和低分化腺癌（OR = 2.36，95%CI：1.03 - 5.39，p = 0.04）。此外，与未扩增的GC患者相比，携带扩增的GC患者生存明显更差（HR = 2.09，95%CI：1.68 - 2.59，p < 0.00001）。总之，本荟萃分析表明，扩增是GC患者的不良预后因素。
